MANTLE-CELL LYMPHOMA

This study tests three different drug combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see which combination works best to shrink tumors and keep the cancer from coming back. Participants receive chemother…

This early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…

This study tests a new drug called sonrotoclax (BGB-11417) in about 125 people with mantle cell lymphoma that has come back or stopped responding to other treatments. The first part finds the safest dose, and the second part checks how well that dose shrinks tumors. The goal is t…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests a combination of two drugs, acalabrutinib and rituximab, in elderly patients (65 and older) with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see how well the drugs control the cancer and what side effects occur. About 53…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests a drug called MK-2140 (zilovertamab vedotin) in people with certain B-cell blood cancers that have come back or not responded to other treatments. About 189 adults with mantle cell lymphoma, Richter's transformation lymphoma, follicular lymphoma, or chronic lymph…

This study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has come back or not responded to treatment, or in older adults newly diagnosed with the disease. The goal is to shrink tumors and control the cancer. About 113 particip…

This study tests the drug ibrutinib in 20 people with a slow-growing type of mantle cell lymphoma that hasn't needed treatment yet. The goal is to see if ibrutinib can stop or slow the cancer from getting worse. Participants take the drug by mouth and are monitored for side effec…

This early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in adults with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose by monitoring side effects. Up to 27 participants…

This study tests a combination of two drugs, ibrutinib and rituximab, in 50 adults with a slow-growing form of mantle cell lymphoma who have not had prior treatment. The main goal is to see how many patients achieve complete remission one year after starting treatment. Researcher…

This study tests whether adding venetoclax to a standard treatment (ibrutinib plus a CD20 antibody) works better for people newly diagnosed with mantle cell lymphoma, a rare blood cancer. About 210 adults aged 18 to 79 will receive either the standard combo or the standard combo …

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This early-phase study tests whether giving acalabrutinib and rituximab followed by brexucabtagene autoleucel (a CAR T-cell therapy) can help control high-risk mantle cell lymphoma in people who have not yet received treatment. About 22 participants will be enrolled. The main goa…

This study tests a new treatment plan for young adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. Participants receive a combination of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy to see if it works better than standard treatments. The…

This study tests whether giving a targeted drug (ibrutinib) and an immunotherapy (rituximab) before standard chemotherapy can improve outcomes for young patients with newly diagnosed mantle cell lymphoma, an aggressive blood cancer. About 131 participants will receive the combina…

This study tests a combination of three drugs (acalabrutinib, lenalidomide, and either rituximab or obinutuzumab) in people with untreated mantle cell lymphoma, a rare blood cancer. About 37 participants will receive the treatment for about a year, followed by ongoing maintenance…

This study tests a new way to grow stem cells from umbilical cord blood to help people with high-risk blood cancers like leukemia and lymphoma recover faster after a bone marrow transplant. About 22 patients will receive the expanded stem cells along with standard chemotherapy an…

This study tests a two-drug combination (ixazomib and rituximab) in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests a drug called acalabrutinib in people with mantle cell lymphoma who had to stop ibrutinib because of bad side effects. The goal is to see if acalabrutinib can shrink or control the cancer without causing the same problems. Nine participants are being treated, and…

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma who have not received prior treatment. The goal is to see how well this appr…

This study tests whether adding a stem cell transplant to standard rituximab maintenance therapy helps people with mantle cell lymphoma live longer. About 689 adults in first complete remission will be randomly assigned to receive either a transplant followed by rituximab or ritu…

This study tested a two-step combination of drugs (rituximab/bendamustine followed by rituximab/cytarabine) in 23 adults with newly diagnosed mantle cell lymphoma who were healthy enough for a stem cell transplant. The goal was to see if this approach could achieve a higher compl…

This early study tests if combining two drugs, glofitamab and lenalidomide, can help people with mantle cell lymphoma that returned or didn't respond to prior treatments, including a BTK inhibitor. About 39 adults with this type of blood cancer will take part. The main goal is to…

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study tests a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see how many patients achieve a complete response (no cancer detected) after treatment. About 50 adults wil…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study looks at stored tissue samples from 160 adults with mantle cell lymphoma whose cancer came back or didn't respond to initial chemotherapy and rituximab. Researchers want to find genetic and cellular clues that explain why the cancer becomes resistant. The goal is to be…